CSL (ASX:CSL) committed to AstraZeneca COVID-19 Vaccine

Company News

by Michael Luu

CSL (AX:CSL) has reiterated its commitment to the contract terms with the Australian Government and AstraZeneca (AZ) to produce 51 million AZ coronavirus vaccine doses.

The company’s statement released last night has raised eyebrows, considering the Australian Government’s recommendation of the Pfizer vaccine for the under-50s. The change in direction of Australia’s vaccine roll-out has presented CSL with the question of other COVID-19 vaccine alternatives. However, the company had previously indicated that its facilities are at production capacity and it will be “challenging” for them to repurpose plants for other vaccines’ production.

Shares in CSL are trading 0.18 per cent lower at $265.47


 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.